Jay Yang, MD
The treatment paradigm of acute myeloid leukemia (AML) has seen 5 FDA approvals in the past 1.5 years, but could be strengthened by novel second-generation FLT3 inhibitors as well as BCL-2 inhibitors, explained Jay Yang, MD.
“It has been really exciting and refreshing as a leukemia physician,” said Yang. “It's always good to have new and better therapies that give us more options for our patients.”
... to read the full story